AFP ELISA Kit

It was extremely urgent to develop some simultaneous and sensitive biosensors for detecting multiplex serum tumor markers (TMs) for early screening of cancers. Herein, a multiplex assay was developed based on the DNA-LaMnO3 (DNA-LMO) perovskite encoded probes and targets mediated competitive replacement strategy. Alpha fetoprotein (AFP), carcinoembryonic antigen (CEA) and prostate specific antigen (PSA) markers were employed as representative target TMs. Aptasensor is prepared by a series of DNA-LMO-M encode probes which were prepared by three hyperbranched DNA firstly immobilized on LMO encapsulating Pb, Cd or Cu ions. Then, three TMs aptamers were labeled on the stirring-rod and hybridized with the probes. After the developed encoded probes was incubated the TMs, the encoded probes corresponding to different TMs can be released into the supernatant through the competitive replacement. The inner metal ion can be simultaneously detected by square wave voltammetry corresponding to various TMs. Since the stirring rod can enrich many encoded probes containing a lot of metal ions, multiplex signal amplification can be realized. Due to the enrichment and easy separation of the stirring rod, the signal-to-noise ratio was also obviously improved and thus to results in good sensitivity and accuracy. Moreover, it took only 20 min to detect three targets which much faster than many same types of aptasensor. Under the optimal conditions, the low detection limit for CEA (3.6 x 10(-4) ng/mL), AFP (3.4 x 10(-4) ng/mL) and PSA (2.8 x 10(-4) ng/mL) were obtained. Therefore, this method is likely to be used for early and sensitive screening of tumors.

Background: Sorafenib has been recommended as the first-line treatment and shown to prolong median overall survival (OS) of patients with advanced unresectable hepatocellular carcinoma (HCC). Recently, a growing amount of research has supported the application of transarterial chemoembolization (TACE) in patients with advanced-stage HCC. The aim of this study was to compare the outcomes of TACE and sorafenib and identify the prognostic factors related to OS for Barcelona Clinic Liver Cancer (BCLC) stage C patients with PS 1 but without vascular invasion or extrahepatic spread. Methods: A total of 323 consecutive patients in BCLC stage C with PS 1 but without vascular invasion or extrahepatic spread were enrolled in this retrospective study. Survival analyses were performed using the Kaplan-Meier analysis, and the statistical differences between the TACE and sorafenib groups were examined by the log-rank test. Univariate and multivariate Cox regression analyses were performed to investigate the prognostic factors for OS. Results: Based on the Kaplan-Meier curves, patients treated with TACE showed a better OS than those undergoing sorafenib, with respective OS at 1, 3, and 5 years (67.7%, 41.5%, 23.2% vs. 55.6%, 29.6%, 4.8%; log-rank P=0.002). The univariate analysis indicated that tumor size, tumor number, and treatment method, along with platelet (PLT), white bkxxl cell (WBC), and alpha-fetoprotein (AFP) count, were associated with OS. The multivariate analysis demonstrated that tumor size, tumor number, and treatment method were significant prognostic factors for OS. According to the subgroups analyses based on the tumor size and tumor number, there were significant differences in OS among overall subsets between TACE and sorafenib therapy. Conclusions: TACE provided better prognostic performance than sorafenib and should be suggested as an alternative treatment modality to sorafenib for BCLC stage C patients with PS 1 but without vascular invasion or extrahepatic spread.